|
業務類別
|
Biotechnology |
|
業務概覽
|
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. |
| 公司地址
| 2001 Market Street, Suite 3915, Unit No. 15, Philadelphia, PA, USA, 19103 |
| 電話號碼
| +1 267 225-7416 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.contexttherapeutics.com |
| 員工數量
| 15 |
| Ms. Jennifer Minai-Azary |
Chief Financial Officer, Principal Accounting Officer and Treasurer |
美元 421.73K |
28/04/2026 |
| Mr. Martin A. Lehr |
Chief Executive Officer, President and Director |
美元 588.52K |
28/04/2026 |
| Mr. Alex Levit |
Chief Legal Officer and Corporate Secretary |
美元 397.81K |
28/04/2026 |
| Ms. Karen Deborah Chagin |
Chief Medical Officer |
-- |
28/04/2026 |
|
|
| Ms. Jennifer Evans Stacey, Esq. |
Independent Director |
28/04/2026 |
| Dr. Karen L. Smith, L.L.M.,M.B.A.,M.D.,PhD |
Independent Director |
28/04/2026 |
| Dr. Luke Nathaniel Walker, M.D. |
Independent Director |
28/04/2026 |
| Mr. Andy Pasternak |
Chairperson of the Board |
28/04/2026 |
| Ms. Linda West |
Independent Director |
28/04/2026 |
| Mr. Martin A. Lehr |
Chief Executive Officer, President and Director |
28/04/2026 |
| Dr. Philip Kantoff, M.D. |
Independent Director |
28/04/2026 |
|
|
|
|
